Conducted at Stanford University School of Medicine
A Clinically Proven Natural Fertility Remedy
Lynn M. Westphal, MD, Mary Lake Polan, MD, PhD, MPH*, Aileen Sontag Trant, PhD
Purpose: To determine the impact of nutritional supplementation on female fertility.
Methods: A double-blind, placebo-controlled study was initiated to determine the effects of
FertilityBlend for Women, a proprietary nutritional supplement containing chasteberry, green tea, L-arginine, vitamins (including folate) and minerals, on progesterone level, basal body temperature, menstrual cycle length, pregnancy rate and side-effects.
Results: Ninety-three (93) women, age 24-42 years, who had tried unsuccessfully to conceive for six to 36 months, completed the study. After three months, the FertilityBlend (FB) supplement group (N=53 vs. 40 in placebo group) demonstrated a strong trend toward an increase in mean mid-luteal phase progesterone (from 8.2 to 10.4 ng/ml, p=0.06). Among women initially low in progesterone (<12 ng/ml, N=34 in FB and 23 in placebo group), the increase in the FB group with low progesterone was highly significant (4.9 to 9.3 ng/ml; p=0.005). The average number of days in cycle with basal temperatures over 98F during luteal phase also increased significantly in the overall FB group (5.5 to 8.1 days, p=0.006). Among women starting with short cycles (<27 days, N=15 in FB and N=9 in placebo group), mean cycle length increased significantly in the FB group (from 24.2 to 27.6 days; p<0.001). Among women with longer cycles (>32 days, N=11 in FB and 6 in placebo group), cycles tended to shorten in the FB group (from 41.6 to 31.7; p=0.02). The placebo group overall (N=40) did not show any notable changes after treatment, in any of the parameters studied. After six months, 17 of the 53 women in the FB group were pregnant (32%), and four of the 40 women in the placebo group were pregnant (10%; p<0.01). No significant side effects were noted.
Conclusion: Nutritional supplementation could provide an alternative or complement conventional fertility therapies.
Clinical and Experimental Obstetrician and Gynecology. XXXIII, n. 4, July 2006.
*Dr. Polan is a member of the Scientific Advisory Board and received stock options in the company for her service.